refractory non-hodgkin lymphoma Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (3)

Phase 1 (1)
Phase 2 (1)
Unknown (1)

Interventional (3)

Hebei Senlang Biotechnology Inc., Ltd. (1)
National Cancer Institute (NCI) (1)
Sanofi (1)

No (3)

No (3)

Adult (18+) (3)
Pediatric (Under 18) (2)

I am/have/had

I am/have/hadrefractory ependymoma

I am/have/hadpercutaneous endoscopic gastrostomy

I am/have/hadcytotoxic chemotherapy

I am/have/hadradiopharmaceutical therapy

I am/have/hadrecurrent melanoma

I am/have/hadrefractory malignant glioma

I am/have/hadtreatment regimen

I am/have/hadbone marrow procedure

I am/have/hadblood transfusion

I am/have/hadimmunohistochemistry

I am/have/hadseizure disorder

I am/have/hadcancer treatment

I am/have/hadpleural effusion

I am/have/hadfollicular lymphoma

I am/have/hadcancer therapy

I am/have/hadmetastasis

I am/have/hadflow cytometry

I am/have/hadmedulloblastoma recurrent

I am/have/hadshake

I am/have/hadmultiple myeloma

added new label for I am/have/had

I am looking for

I am looking forcorticosteroids

I am looking forinterferon

I am looking forcytokines

I am looking forpediatric

I am looking fortumor markers

I am looking fortipifarnib

I am looking forantineoplastic agents

I am looking forantineoplastic

I am looking fornitrosoureas

I am looking forhematopoietic growth factors

I am looking forradiopharmaceutical

I am looking forgrowth factor

I am looking forinterleukins

I am looking foriobenguane

I am looking for131i-mibg

I am looking foranticonvulsants

I am looking fornitrosourea

I am looking foranti-cancer agents

I am looking forchemotherapeutic agents

I am looking foranticancer agents

added new label for I am looking for

Advanced Filters

Found 3 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

For pediatric ages
For Seniors
Recruiting in 10s
Interventional Study
all
Hematology
Recruiting

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

This is a study of patients with relapsed or refractory non-Hodgkin's lymphoma. To evaluate the safety and efficacy of SL1904B in patients with relapsed or refractory non-Hodgkin's lymphoma.

immunohistochemistry

absolute neutrophil count

hodgkin's disease

non-hodgkin lymphoma

lymphoma

0 views
19 Feb, 2024

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

excisional biopsy

diffuse large b-cell lymphoma

ct scan

recurrent disease

hair thinning

0 views
19 Feb, 2024
5 locations

Phase 2
For pediatric ages
For adults
Recruiting in 10s
Interventional Study
all
Endocrinology
Recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

refractory ependymoma

percutaneous endoscopic gastrostomy

radiopharmaceutical therapy

cytotoxic chemotherapy

recurrent melanoma

0 views
19 Feb, 2024